Clinical Trials Directory

Trials / Completed

CompletedNCT05448638

Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery

Quality of Recovery Scores in Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block Versus Pectoral Nerves Block for Breast Cancer Surgery: a Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
116 (actual)
Sponsor
Zhejiang Cancer Hospital · Academic / Other
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, randomized, controlled trial for evaluating the efficacy of addition of transversus thoracic muscle plane block to pectoral nerves block versus pectoral nerves block for quality of recovery scores in breast cancer surgery.

Detailed description

The pectoral nerves (PECS) block cannot block the most internal mammary region, whereas a transversus thoracic muscle plane (TTP) block can. The combination of PECS and TTP blocks may be suitable for breast cancer surgery. We studied patients undergoing breast cancer surgery to assess whether the combination of PECS and TTP blocks provides better postoperative recovery than PECS block alone.

Conditions

Interventions

TypeNameDescription
PROCEDUREthe combination of transversus thoracic muscle plane and pectoral nerves blocksFor the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle. For the transversus thoracic muscle plane block, ropivacaine 0.375%,15ml was injected between the transversus thoracic muscle and the internal intercostal muscle.
PROCEDUREthe pectoral nerves block onlyFor the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle.

Timeline

Start date
2022-07-12
Primary completion
2023-05-05
Completion
2023-08-05
First posted
2022-07-07
Last updated
2023-11-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05448638. Inclusion in this directory is not an endorsement.